TYRA
Tyra Biosciences, Inc.Healthcare·Biotechnology
$33.41
$2.0B market cap
Revenue
$0.0M
Free Cash Flow
$-56.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and
2-Year Price History
$32.47+100.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -41.9 | -42.0 | -39.3 | -32.6 | -32.7 | -0.1 | 383.5 | 5.7 | 61.8 | -77.4% | -- | -- |
| Act | 2025-Q4 | 0.0 | -36.4 | -36.5 | -33.8 | -23.6 | -23.7 | -0.1 | 256.0 | 5.8 | 59.6 | -162.3% | -- | -- |
Valuation & Metrics
Market Stats
Price$33.41
Market Cap$2.0B
Enterprise Value$1.6B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.8%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-73.1M
Free Cash Flow$-56.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-119.8%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares7.7M
Days to Cover6.7
Change (vs Prior)+0.0%
Need at least 2 settlement dates for chart
Employees
Headcount60
Revenue / Employee$0
Gross Profit / Employee$-2,300
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
116.9%(+93.4% YoY)
146 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
11.6%(+9.7% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.2%(+0.1% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $467M | $14.14 | +$0 | +$59.8M | -4.9% | $9.44B |
| FMR LLC | $297M | $33.38 | +$296M | +$231M | -0.0% | $1.89T |
| Nextech Invest, Ltd. | $155M | $9.30 | +$0 | +$0 | +25.9% | $1.42B |
| JANUS HENDERSON GROUP PLC | $149M | $20.97 | +$36.6M | +$45.8M | +1.2% | $209.29B |
| Alta Partners Management Company, L.P. | $146M | $13.90 | +$0 | −$9.8M | +1.6% | $151M |
| FARALLON CAPITAL MANAGEMENT LLC | $137M | $27.23 | +$58.0M | +$93.3M | -0.4% | $15.27B |
| TCG Crossover Management, LLC | $124M | $12.86 | +$13.4M | +$13.4M | +4.4% | $3.50B |
| Commodore Capital LP | $94.8M | $9.85 | −$34.5M | +$58.4M | -0.3% | $1.73B |
| BlackRock, Inc.Passive | $84.9M | $22.56 | +$5.0M | +$20.0M | -0.2% | $5.69T |
| Paradigm Biocapital Advisors LP | $78.7M | $38.30 | +$78.7M | +$78.7M | +2.0% | $4.69B |
| BVF INC/IL | $75.7M | $16.31 | −$5.8M | −$75.4M | -0.5% | $3.14B |
| Caligan Partners LP | $48.9M | $22.04 | +$12.7M | +$48.0M | +6.7% | $1.41B |
| STATE STREET CORPPassive | $46.6M | $29.40 | +$17.9M | +$30.7M | -0.2% | $2.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $43.1M | $38.30 | +$43.1M | +$43.1M | — | $4.04T |
| 5AM Venture Management, LLC | $39.4M | $15.86 | +$0 | +$3.4M | +0.7% | $360M |
| PRICE T ROWE ASSOCIATES INC /MD/ | $37.8M | $37.91 | +$37.2M | +$37.8M | -0.2% | $864.93B |
| Logos Global Management LP | $32.6M | $35.69 | +$24.5M | +$32.6M | -1.6% | $1.94B |
| BARCLAYS PLC | $31.9M | $36.05 | +$29.0M | +$30.3M | -0.1% | $279.69B |
| Canaan Partners XI LLC | $28.7M | $7.15 | −$101M | −$130M | -0.5% | $76.1M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $25.2M | $15.68 | +$28K | +$5.4M | +2.3% | $1.61T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+2.96%
avg per quarter
Holders (ex-self)
+1.55%
excl. this stock
Buyers (this Q)
+1.01%
94 buyers · $0.99B in
Sellers (this Q)
+4.24%
46 sellers · $0.13B out
alpha coverage: 98% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+24.0%
how holders react when this stock falls
On quiet Qs
+17.9%
−10% to +10% baseline
On rallies (+10%+)
-0.6%
how they react when this stock rises
Holders' portfolio flow this Q
-0.1%
outflows — trims may be forced
Sellers' portfolio flow this Q
-25.6%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.3%
Holder mid (any stock)
-0.4%
Holder rally (any stock)
-1.9%
Biggest decreases this quarter
Canaan Partners XI LLC−$101Mα-0.5Kynam Capital Management, LPexited−$41.1MCommodore Capital LP−$34.5Mα-0.3Trails Edge Capital Partners, LPexited−$18.4MBALYASNY ASSET MANAGEMENT LLC−$17.9Mα-0.4BOONE CAPITAL MANAGEMENT LLCexited−$10.5MBVF INC/IL−$5.8Mα-0.5DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)−$2.9MINVESTMENT COUNSEL CO OF NEVADAexited−$2.2MSUPERSTRING CAPITAL MANAGEMENT LPexited−$1.5M
New buyers this quarter
Top-5 holders · 48.1%
RA CAPITAL MANAGEMENT, L.P.--
FMR LLC--
Nextech Invest, Ltd.--
JANUS HENDERSON GROUP PLC--
Alta Partners Management Company, L.P.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.12.2MFMR LLC7.7MNextech Invest, Ltd.4.1MBoxer Capital, LLC—JANUS HENDERSON GROUP PLC3.9MAlta Partners Management Company, L.P.3.8MFARALLON CAPITAL MANAGEMENT LLC3.6MTCG Crossover Management, LLC3.2MBVF INC/IL2.0MCanaan Partners XI LLC750K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| LBRX | LB Pharmaceuticals Inc Common Stock | 4 | 227.57× |
| GHRS | GH Research PLC | 3 | 227.57× |
| CGEM | Cullinan Therapeutics, Inc. | 3 | 195.06× |
| RLAY | Relay Therapeutics, Inc. | 5 | 162.55× |
| TNGX | Tango Therapeutics, Inc. | 5 | 151.71× |
| GLUE | Monte Rosa Therapeutics, Inc. | 3 | 151.71× |
| PHVS | Pharvaris N.V. | 6 | 151.71× |
| SION | Sionna Therapeutics, Inc. | 3 | 136.54× |
| SYRE | Spyre Therapeutics, Inc. | 5 | 133.87× |
| NUVL | Nuvalent, Inc. | 4 | 121.37× |
| BCRX | BioCryst Pharmaceuticals, Inc. | 3 | 113.79× |
| PCVX | Vaxcyte, Inc. | 6 | 113.79× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$54.006160.0%
Last Year (8 analysts)$47.004070.0%
Current Price$33.41
Analyst Ratings
7
Buy: 7Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$11.22M
16 txns · 3 insiders · 613,558 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$15.32M
6 txns · 1 insider · 1,561,335 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-25 | SELL | KAPLAN GILLA | director | 14,295 | $36.97 | $529K | $1.04M |
| 2026-02-12 | SELL | Bensen Daniel | officer: Chief Discovery Officer | 8,000 | $32.87 | $263K | $4.83M |
| 2026-01-12 | SELL | Bensen Daniel | officer: Chief Discovery Officer | 8,000 | $28.52 | $228K | $4.42M |
| 2025-12-19 | SELL | MORE ROBERT J | director | 10,000 | $25.00 | $250K | $95.59M |
| 2025-12-12 | SELL | Bensen Daniel | officer: Chief Discovery Officer | 8,000 | $22.64 | $181K | $3.69M |
| 2025-11-21 | SELL | MORE ROBERT J | director | 246,871 | $20.25 | $5.00M | $77.64M |
| 2025-11-19 | SELL | Bensen Daniel | officer: Chief Operating Officer | 49,956 | $16.32 | $815K | $2.79M |
| 2025-11-18 | SELL | Bensen Daniel | officer: Chief Operating Officer | 75,633 | $16.07 | $1.22M | $3.55M |
| 2025-11-17 | SELL | Bensen Daniel | officer: Chief Operating Officer | 20,072 | $16.18 | $325K | $4.80M |
| 2025-11-14 | SELL | Bensen Daniel | officer: Chief Operating Officer | 110,228 | $16.02 | $1.77M | $5.07M |
| 2025-11-13 | SELL | Bensen Daniel | officer: Chief Operating Officer | 1,111 | $16.00 | $18K | $6.83M |
| 2025-06-18 | SELL | KAPLAN GILLA | director | 9,568 | $9.78 | $94K | $276K |
| 2025-06-17 | SELL | KAPLAN GILLA | director | 10 | $10.35 | $104 | $391K |
| 2025-06-16 | SELL | KAPLAN GILLA | director | 6,814 | $10.38 | $71K | $392K |
| 2025-06-16 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 11,813 | $10.13 | $120K | $103.93M |
| 2025-06-13 | SELL | KAPLAN GILLA | director | 15,000 | $10.31 | $155K | $460K |
| 2025-06-13 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 120,167 | $10.20 | $1.23M | $104.52M |
| 2025-06-12 | SELL | KAPLAN GILLA | director | 30,000 | $10.31 | $309K | $615K |
| 2025-06-12 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 31,307 | $10.20 | $319K | $103.30M |
| 2025-06-09 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 186,850 | $10.19 | $1.90M | $102.88M |
Order Flow (FINRA, ~3w lag)
11.6%retail-14.8pp
35.8%dark+7.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
TYRA BIOSCIENCES: Clinical-Stage Burn with Significant Dilution Overhang and Insider Plan Terminations
Overall Risk
6/10
Fraud
3/10
Dilution
8/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
8/10